What are the new demands on disease management programs? Which regulatory agencies are responsible for these demands? Are there risks to the demands and are there behavior limitations to these management programs? In your discussion, provide examples of two successful Disease Management Programs from real life. Why were these programs successful? Can they be replicated in other settings? What are the challenges to replication? Include two APA citations© BrainMass Inc. brainmass.com October 25, 2018, 7:06 am ad1c9bdddf
If this is a paper that is to include ideas from these responses, you must put an introduction and conclusion. Refer to the references, which will give you additional information where you see fit.
What are the new demands on disease management programs? Which regulatory agencies are responsible for these demands? Are there risks to the demands and are there behavior limitations to these management programs? In your discussion, provide examples of two successful Disease Management Programs from real life. Why were these programs successful? Can they be replicated in other settings? What are the challenges to replication? Include two APA citations
1. What are the new demands on disease management programs?
Disease management programs are designed to produce specific outcomes, which include improving patients' clinical condition, lowering cost, and improving patient's quality of life (Menon, 2012). Focusing on health care needs as a set of conditions not as one specific disease is one of the new demands on DM. Because patient's illness may incorporate more than one disease, disease management programs need to improve by focusing on more than one disease to improve the quality of healthcare. The second is the new health care demands from baby boomers. "The leading edge of the "junior seniors" has already crossed the threshold of their 55th year, and by sheer weight of numbers they're beginning to reverse a decade's worth of shrinking utilization rates as the creaks and groans of middle age begin to turn to higher rates of disease" (Carrol, 2012).
2. Which regulatory agencies are responsible for these demands?
Disease Management Organizations (DMO) are comprised of educated, licensed, and or certified employees who integrate their action in accordance with sponsors, Clinical Practice Guidelines (CPG) and Federal ...
The solution discusses new demands on disease management programs.
Organizational Chart - International Business Management
Healthcare in Taiwan
Our company will be a small niche medical company located in Taiwan. The company will employ about 60 people. These employees will consist of operations personnel and company staff such as Medical Doctors, Occupational Medical Director, Registered Nurses, Employee Health Safety staff, and Benefits Advisor. The building itself will have three floors with the main floor being for prescription drug storage, customer service, and offices, while bottom floor contains more offices is primarily for rehabilitation for the elderly and the upper floor will be used for laboratory research and development and diagnostics
The products that the company will hold are products that are affiliated with the ongoing health issues in Taiwan such as, heart disease, cancer, and rehabilitation. The product that will be held for heart disease will consist of Accupril, Inspra, and Norvasc. These medicines are the most prescribed brand name high blood pressure medicines worldwide. They help to treat high blood pressure, heart failure, and easy blood flow through arteries. Cancer products will consist of Aromasin, Camptosar, and Ellence. These medicines are used for the treatment of breast cancer, colon cancer, and the rid of any tumor cells in the body.
With the continuing health concerns in Taiwan the National Health Insurance program accounts for more than 60 percent of all health costs. Taiwan is also very advanced in technology and with that technology used for research and development our company seeks to make substantial profits.
The company will like to expand internationally for various reasons. Taiwan's economy is ranked among the 20 largest in the US. And at the same time, Taiwan also has an increasingly growing population which is spending a big amount of their income on healthcare. There is strong demand in Taiwan for numerous medial products and services. Some of which include those related to orthopedics, rehabilitation, cardiology, and diagnosis particularly pertaining to cancer. Additionally, due to increased male and female life expectancy in Taiwan, the demand for medial products for senior citizens continues to grow. In part, the United States has exported approximately USD 161 million in medial products to Taiwan in 2003 1. For this reason, a distributor in Taiwan can assist US exporters with the process.
Taiwan's market offers ample opportunities for US firms to profit from a strong and growing demand for advanced medical supplies. They have an aging population together combined with other factors such as high population density. In 2004, the average per capita expenditure on healthcare was US$847 of a total per capita GDP of $13,529 2.
Our company will profit from the sales of medial products for the elderly, more specifically for heart disease and cancer patients, two of the leading causes of death in Taiwan. In Taiwan, the overall medical device market is projected to grow at a rate of 3-5 percent per year while implantable devices grow at an annual rate of 6-10 percent2.
The Taiwan market for implantable devices has been growing rapidly as a result of their growing elderly population and patients increased awareness of new implant technologies. One of our company's major forces for improving the healthcare of Taiwan's population are the new innovations in medial devices. Cardiovascular and hear diseases are the two leading causes of death in Taiwan that have highly contributed for the demand of heart implants. The Taiwan market's demand for implantable medical devices was forecasted to reach approximately US$123.4 million in 2005. The market demand grew 29.5 percent from its previous years2. For years the US supplies 90% of Taiwan's vascular grafts, 80% of ACID and artificial heart valves and 70% of intraocular lenses2. Taiwan's economy continues to grow steadily and our company is looking forward to expanding internationally to Taiwan.
Taiwan is the seventh largest trading partner of the US with over US$50 billion in two-way trade . The region is an excellent market for many types of products and services and our company will take advantage of this opportunity. In conclusion, we will provide medical products that will improve the healthcare technologies sector.
(See attached files for full problem description)View Full Posting Details